BOSTON, May 7, 2015 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity, today announced that the company has been selected to present an oral presentation and two poster presentations at the 22nd European Congress on Obesity in Prague, Czech Republic on May 7-8, 2015.
"We are extremely pleased to have been given the opportunity to present the positive findings from the ZAF-211 study for our investigational drug beloranib, which has the potential to treat many patients suffering from severe obesity in Prader-Willi syndrome, hypothalamic injury-associated obesity, including craniopharyngioma-associated obesity, and severe obesity in the general population," said Thomas Hughes, Ph.D., Chief Executive Officer.
The abstracts Zafgen will present at the 22nd European Congress on Obesity are detailed below:
Title: Randomized, Double-Blind, Placebo Controlled 4 Week Proof of Concept Trial of Beloranib Resulted in Rapid and Significant Weight Loss in Patients with Hypothalamic Injury Associated Obesity
Presenting Author: Jaret L. Malloy, Ph.D
Oral Presentation Date/Time: Thursday, May 7, 2015, 11:30 am – 1:00 pm
Oral Session Name: Track 8 Oral Session on Co-morbidities
Room/Details: Forum Hall, Prague Conference Center
Title: Randomized, Double-Blind, Placebo-Controlled, 4-Week Proof of Concept Trial of Beloranib, A Novel Treatment for Patients with Prader-Willi Syndrome
Presenting Author: Dennis Kim, M.D.
Poster Board Number: PO.111
Presentation Date/Time: Friday, May 8, 2015, 1:15-2:45 pm
Room/Details: Exhibition Hall, Prague Conference Center
Title: In a Phase 2 Study, Beloranib, a Novel Methionine Aminopeptidase 2 (MetAP2) Inhibitor, Appeared Safe and Showed Significant Body Weight Loss Over 12 Weeks in Obese Adults
Presenting Author: Kristin Taylor, Ph.D
Poster Board Number: PO.112
Presentation Date/Time: Friday, May 8, 2015, 1:15-2:25 pm
Room/Details: Exhibition Hall, Prague Conference Center
About Zafgen, Inc.
Zafgen (Nasdaq:ZFGN) is a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity. Beloranib, Zafgen's lead product candidate, is a novel, first-in-class, twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in Prader-Willi syndrome, hypothalamic injury-associated obesity, including craniopharyngioma-associated obesity, and severe obesity in the general population. Zafgen was founded in 2005 to explore novel approaches to obesity therapeutics, including agents known to inhibit MetAP2 that had been found to drive unprecedented weight loss and metabolic improvements in mice. The company is located in Boston, MA.